Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Coluracetam | Piracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 20-80 mg/day divided into 2-3 doses | 1200-4800 mg/day divided into 2-3 doses |
| Timing | Morning and early afternoon. Sublingual administration may provide faster onset. With or without food. | With or without food; split doses morning and afternoon to maintain plasma levels |
| Cycle Duration | Cycles of 4-8 weeks on, 2-4 weeks off | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Enhances high-affinity choline uptake (HACU) via a unique mechanism distinct from other racetams — it increases HACU even in damaged cholinergic neurons, suggesting a choline uptake enhancement rather than mere stimulation. This HACU enhancement persists even after the compound has been cleared, indicating a lasting modification of choline transporter activity. Also shows affinity for AMPA receptors.
20-80 mg/day divided into 2-3 doses
Morning and early afternoon. Sublingual administration may provide faster onset. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off
Positive allosteric modulator of AMPA receptors, binding at a unique site along the dimer interface to reduce desensitization and deactivation. Inhibits N-type calcium channels at clinically relevant CNS concentrations. Enhances membrane fluidity of neuronal phospholipids and modulates neurotransmission across cholinergic and glutamatergic systems.
1200-4800 mg/day divided into 2-3 doses
With or without food; split doses morning and afternoon to maintain plasma levels
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →